<DOC>
	<DOCNO>NCT02194842</DOCNO>
	<brief_summary>The objective randomized phase III open label trial ass upfront combination enzalutamide Ra223 improve radiological progression-free survival compare enzalutamide single agent asymptomatic mildly symptomatic castration resistant prostate cancer patient metastatic bone .</brief_summary>
	<brief_title>Phase III Radium 223 mCRPC-PEACE III</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically confirm diagnosis prostate adenocarcinoma : 1 . Asymptomatic mildly symptomatic ( defined opioids Brief Pain Inventory score ) 2 . Metastatic bone ≥ 2 bone metastasis ( area increase uptake 99mTC BS ( Technetium99m bone scintigraphy ) confirm standard XRay , Computed tomography ( CT ) , Magnetic resonance imaging ( MRI ) ) without additional lymph node metastasis . Visceral metastasis allow 3 . Progressive Castrationresistant prostate cancer ( CRPC ) accord Prostate Cancer Working Group 2 ( PCWG2 ) i.e . either : For patient manifest disease progression solely rise Prostatespecific antigen ( PSA ) level . PCWG2 criterion require documentation sequence rise PSA value minimum 1week interval last value ≥ 2 ng/ml . For patient disease progression manifest bone , irrespective progression rise PSA , PCWG2 guideline require appearance 2 new lesion . Ambiguous result confirm image modality bone scan xray ( e.g . : CTscan MRI ) . For patient disease progression manifest nodal site , irrespective progression rise PSA , PCWG2 require progression accord RECIST 1.1 . Ongoing androgen deprivation therapy LHRH ( Human luteinizing hormonereleasing hormone ) agonist antagonist bilateral orchiectomy Patients must least 18 year old WHO Performance status 01 Charlson score ≤ 3 Castrate serum level testosterone ( &lt; 50 ng/dL ) Biochemistry hematology : 1 . Adequate bone marrow function ( absolute neutrophil count 1.5109/L ; platelet 100 109/L , hemoglobin &gt; = 10.0 g/dl. ) . 2 . Total bilirubin level ≤ 1.5 x institutional upper limit normal ( ULN ) , except patient Gilbert 's disease 5.0 ULN 3 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; = 2.5 x ULN 4 . Creatinine &lt; or= 1.5 x ULN 5 . Albumin &gt; 25 g/L Normal cardiac function accord local standard 12lead Electrocardiogram ( ECG ) ( complete , standardize 12lead record ) Able swallow study drug comply study requirement Prior concomitant therapy 1 . Prior docetaxel permit following condition : start within 2 month Androgen deprivation therapy ( ADT ) initiation , give maximum 6 cycle progression within 6 month last dose docetaxel . 2 . Previous treatment bicalutamide , flutamide , prednisone , dexamethasone allow stop least 4 week prior entry study 3 . Patients take bisphosphonates denosumab eligible receive stable dose 4 week prior randomization . ( These treatment may continue study ) use adequate birth control measure study treatment period least 3 month last dose enzalutamide 6 month last dose Ra223 . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial Before patient randomization , write informed consent must give accord ICH/GCP , national/local regulation No known history central nervous system metastasis leptomeningeal tumor spread . No significant cardiovascular disease include : 1 . Myocardial infarction within 6 month prior screen 2 . Uncontrolled angina within 3 month prior screen 3 . Congestive heart failure New York Heart Association ( NYHA ) class III IV , patient history congestive heart failure NYHA class III IV past , unless screen echocardiogram multigated acquisition scan ( MUGA ) perform within 3 month result leave ventricular ejection fraction ≥ 45 % 4 . History clinically significant ventricular arrhythmia ( e.g. , ventricular tachycardia , ventricular fibrillation , torsades de pointes ) 5 . History Mobitz II second degree third degree heart block without permanent pacemaker place 6 . Uncontrolled hypertension indicate rest systolic blood pressure &gt; 170 mm Hg diastolic blood pressure &gt; 105 mm Hg screen 7 . Hypotension indicate systolic blood pressure &lt; 86 millimeter mercury ( mm Hg ) screen 8 . Bradycardia indicate heart rate &lt; 45 beat per minute screen ECG physical examination patient receive docetaxel CRPC exclude . No prior treatment enzalutamide Ra223 No prior concomitant treatment Cyp17 inhibitor ( abiraterone , orteronel ) ketoconazole No prior hemibody external radiotherapy . Patients receive type prior external radiotherapy allow provide bone marrow function assess meet protocol requirement hemoglobin , absolute neutrophil count platelets No prior therapy radionuclides ( e.g. , strontium89 , samarium153 , rhenium186 , rhenium188 ) No involvement another therapeutic trial involve experimental drug No anticancer therapy treatment another investigational agent within last 4 week prior randomization No known hypersensitivity compound related enzalutamide Ra223 No prior history malignancy prostate adenocarcinoma ( except patient basal cell , squamous cell carcinoma skin , insitu carcinoma lowgrade superficial bladder cancer ) , patient free malignancy period 3 year prior randomization date No history seizure , include febrile seizure , loss consciousness , transient ischemic attack within 12 month enrollment ( registration date ) , condition may predispose seizure ( e.g. , prior stroke , brain arteriovenous malformation , head trauma loss consciousness require hospitalization ) No major surgery within 4 week prior treatment No intake narcotic analgesia bone pain No drug alcohol abuse No serious illness medical condition , limit : 1 . Any infection ≥ Grade 2 accord National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) version 4 2 . No gastrointestinal disorder affect absorption ( e.g. , gastrectomy active peptic ulcer disease ) 3 . Crohn 's disease ulcerative colitis 4 . Bone marrow dysplasia 5 . Fecal incontinence 6 . Lifethreatening illness unrelated cancer No condition , investigator 's opinion , make patient unsuitable trial participation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>metastatic</keyword>
	<keyword>prostate cancer</keyword>
</DOC>